The nifedipine gastrointestinal therapeutic system (GITS). Evaluation of pharmaceutical, pharmacokinetic and pharmacological properties

Clinical Pharmacokinetics

Volumn 30, Issue 1, 1996, Pages 28-51

  Grundy, John S ^a   Foster, Robert T ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

FELODIPINE; LIVER ENZYME; METOPROLOL; NIFEDIPINE; OXPRENOLOL; VERAPAMIL;

ADVERSE DRUG REACTION; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG INTERACTION; DRUG MANUFACTURE; DRUG METABOLISM; DRUG RELEASE; DRUG THERAPY; EDEMA; ESSENTIAL HYPERTENSION; FLUSHING; FOOD DRUG INTERACTION; FOOD INTAKE; FRUIT JUICE; GASTROINTESTINAL MOTILITY; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PH; PHARMACEUTICS; PHARMACOKINETICS; PHARMACOLOGY; PRIORITY JOURNAL; REVIEW; TACHYCARDIA; TREATMENT OUTCOME;

EID: 0030045954     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199630010-00003     Document Type: Review

References (131)

1. Sorkin EM, Clissold SP, Brogden RN. Nifedipine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders. Drugs 1985; 30: 182-274
2. Singl BN. Calcium channel blockade and cardiovascular therapeutics. In: Parmley WW, Chatterjee K, editors. Cardiovascular pharmacology. London: Wolfe, 1994: 6.1-6.27
3. Reicl er-Reiss H, Barasch E. Calcium antagonists in patients with heart failure: a review. Drugs 1991; 42 (3): 343-64
4. Licht en PR, Hugenholtz PG. Rafflenbeul W, et al. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). Lancet 1990; 335 (8698): 1109-13
5. Eranko PO, Palva ES, Konno K, et al. Regulatory control of synonym drug bioavailability: bioinequivalency of nifedipine preparations. Pharm Med 1990; 4: 197-205
6. Kleinbloesem CH, van Brummelen P, van de Linde JA, et al. Nifedipine: kinetics and dynamics in healthy subjects. Clin Pharmacol Ther 1984; 35 (6): 742-9
7. Foster TS, Hamann SR, Richards VR, et al. Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects. J Clin Pharmacol 1983; 23: 161-70
8. Kleinbloesem CH, van Brummelen P, Breimer DD. Nifedipine: relationship between pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 1987; 12: 12-29
9. Kleinbloesem CH, van Brummelen P, Danhof M, et al. Rate of increase in the plasma concentration of nifedipine as a major determinant of its hemodynamic effects in humans. Clin Pharmacol Ther 1987; 41 (1): 26-30
10. Steinijans VW. Pharmacokinetic characterization of controlled-release formulations. Eur J Drug Metab Pharmacokinet 1990; 15 (2): 173-81
11. Devane JG, Mulligan S, Kavanagh M, et al. New developments in sustained-release antihypertensive therapy: formulation and pharmacokinetic considerations. Am J Cardiol 1992; 69: 23E-27E
12. van Zwieten PA, Pfaffendorf M. Pharmacology of the dihydropyridine calcium antagonists: relationship between lipophilicity and pharmacodynamic responses. J Hypertens 1993; II Suppl. 6: S3-8
13. Prisant LM, Bottini B, DiPiro JT, et al. Novel drug-delivery systems for hypertension. Am J Med 1992; 93 Suppl. 2A: 45S-55S
14. Avgerinos A, Gorrod JW. Pharmacokinetics of nifedipine Jerived from a new retard tablet formulation. Eur J Drug Metab Pharmacokinetic 1990; 15 (4): 273-8
15. Pabst G, Lutz D, Molz KH, et al. Pharmacokinetics and bioavailability of three different galenic nifedipine preparations. Arzneium Forsch 1986; 36 (1): 256-60
16. Swanson DR, Barclay BL, Wong PS, et al. Nifedipine gastrointestinal therapeutic system. Am J Med 1987; 83 Suppl. 6B: 3-9
17. Kelly JG, O'Malley K. Clinical pharmacokinetics of calcium antagonists: an update. Clin Pharmacokinet 1992; 22 (6): 416-33
18. Michelson EL. Calcium antagonists in cardiology: update on sustained-release drug delivery systems. Clin Cardiol 1991; 14: 947-50
19. Data on file. Etobicoke. Ontario: Bayer Canada Inc., 1995
20. Santus G, Baker RW. Osmotic drug delivery: a review of the patent literature. J Control Release 1995; 35: 1-21
21. Kellaway IW. Scientific rationale and clinical implications of sustained-release formulations. Br J Clin Pract 1988; 60 Symp. Suppl.: 9-13
22. Theeuwes F. Elementary osmotic pump. J Pharm Sci 1975; 64 (12): 1987-91
23. Chung M, Reitberg DP, Gaffney M, et al. Clinical pharmacokinetics of nifedipine gastrointestinal therapeutic system. A controlled-release formulation of nifedipine. Am J Med 1987; 83 Suppl. 6B: 10-4
24. Qureshi SA, Caille G, Brien R, et al. Applicalion of flow-through dissolution method for the evaluation of oral formulations of nifedipine. Drug Dev Ind Pharm 1994; 20 (11): 1869-82
25. Grundy JS, Foster RT, Grace M, et al. A single dose pharmacokinetic (PK) comparison of prolonged-action (PA) and gastrointestinal therapeutic system (GITS) nifedipine (NIF) in elderly volunteers [abstract]. Pharmaceut Res 1994; 11 (10): S-401
26. Crome P, Muller FO, Wijayawardhana P, et al. Single dose and steady-state pharmacokinetic profiles of nifedipine GITS tablets in healthy elderly and young volunteers. Drug Invest 1993; 5 (4): 193-9
27. Schneider R, Stolero D, Griffel L, et al. Pharmacokinetic profile of nifedipine GITS in hypertensive patients with chronic renal impairment. Drugs 1994; 48 Suppl. 1: 16-22
28. Raemsch KD, Sommer J. Pharmacokinetics and metabolism of nifedipine. Hypertension 1983; 5 (4 Suppl. 2): 19-24
29. Soons PA, Schoemaker HC, Cohen AF, et al. Intraindividual variability in nifedipine pharmacokinetics and effects in healthy subjects. J Clin Pharmacol 1992; 32: 324-31
30. Reitberg DP, Love SJ, Quercia GT, et al. Effect of food on nifedipine pharmacokinetics. Clin Pharmacol Ther 1987; 42 (1): 72-5
31. Challenor V, Waller DG, Gruchy BS, et al. The effects of food and posture on the pharmacokinetics of a biphasic release preparation of nifedipine. Br J Clin Pharmacol 1986; 22: 565-70
32. Myers MG, Raemsch KD. Comparative pharmacokinetics and antihypertensive effects of the nifedipine tablet and capsule. J Cardiovasc Pharmacol 1987; 10 Suppl. 10: S76-8
33. Ahsan CH, Renwick AG, Macklin B, et al. Ethnic differences in the pharmacokinetics of oral nifedipine. Br J Clin Pharmacol 1991; 31: 399-403
34. Qureshi S, Laganiere S, Caillé G, et al. Effect of an acute dose of alcohol on the pharmacokinetics of oral nifedipine in humans. Pharm Res 1992; 9 (5): 683-6
35. Robertson DR, Waller DG, Renwick AG, et al. Age-related changes in the pharmacokinetics and pharmacodynamics of nifedipine. Br J Clin Pharmacol 1988; 25: 297-305
36. Taburet AM, Singlas E, Colin JN, et al. Pharmacokinetic studies of nifedipine tablet. Correlation with antihypertensive effects. Hypertension 1983; 5 (4 Suppl. 2): 29-33
37. Scott M, Castleden CM, Adam HK, et al. The effect of ageing on the disposition of nifedipine and atenolol. Br J Clin Pharmacol 1988; 25: 289-96
38. Sigusch H, Hippius M, Henschel L, et al. Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation. Pharmazie 1994; 49: 522-4
39. Hoyo-Vadillo C, Castañeda-Hernández G, Herrera JE, et al. Pharmacokinetics of nifedipine slow release tablet in Mexican subjects: further evidence for an oxidation polymorphism. J Clin Pharmacol 1989; 29: 816-20
40. Akopov SE, Sarkissian MA, Grigorian GS, et al. Nifedipine kinetics and dynamics in hypertensive patients: a new approach. Int J Clin Pharmacol Ther 1994; 32 (6): 317-20
41. Ueno K, Kawashima S, Uemoto K, et al. Effect of food on nifedipine sustained-release preparation. DICP 1989; 23: 662-5
42. Grundy JS, Foster RT, du Souich P, et al. A single-dose pharmacokinetic (PK) comparison of three prolonged-action (PA) nifedipine (NIF) formulations [abstract]. Pharm Res 1994; 11 (10): S401
43. Groenewoud G, Luus HG, Müller FO, et al. Pharmacokinetics of nifedipine GITS after single dose and at steady-state in healthy elderly and young subjects [abstract]. S Afr Med J 1991; 80: 623
44. Khan A, Langley SJ, Mullins FG, et al. The pharmacokinetics and pharmacodynamics of nifedipine at steady state during concomitant administration of cimetidine or high dose ranitidine. Br J Clin Pharmacol 1991; 32: 519-22
45. Debbas NM, Jackson SH, Shah K, et al. The bioavailability and pharmacokinetics of slow release nifedipine during chronic dosing in volunteers. Br J Clin Pharmacol 1986; 21: 385-8
46. Schall R, Muller FO, Hundt HK, et al. Relative bioavailability of four controlled-release nifedipine products. Biopharm Drug Dispos 1994; 15: 493-503
47. Guengerich FP, Brian WR, Iwasaki M, et al. Oxidation of dihydropyridine calcium channel blockers and analogues by human liver cytochrome P-450 IIIA4. J Med Chem 1991; 34: 1838-44
48. Guengerich FP, Martin MV, Beaune PH, et al. Characterisation of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 1986; 261 (11): 5051-60
49. Krishna DR, Klotz U. Extrahepatic metabolism of drugs in humans. Clin Pharmacokinet 1994; 26 (2): 144-60
50. Edgar B, Bailey DG, Bergstrand R, et al. Formulation dependent interaction between felodipine and grapefruit juice [abstract]. Clin Pharmacol Ther 1990; 47 (2): 181
51. Challenor VF, Waller DG, Renwick AG, et al. The trans-hepatic extraction of nifedipine. Br J Clin Pharmacol 1987; 24: 473-7
52. Murdoch D, Brogden RN. Sustained release nifedipine formulations: an appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders (published erratum appears in Drugs 1991 Aug: 42 (2): 330]. Drugs 1991; 41: 737-79
53. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker Inc., 1982
54. Boxenbaum H. Pharmacokinetic determinants in the design and evaluation of sustained-release dosage forms. Pharm Res 1984; 82-8
55. Ilett KF, Tee LBG, Reeves PT, et al. Metabolism of drugs and other xenobiotics in the gut lumen and wall. Pharmacol Ther 1990; 46: 67-93
56. de Boer AG, Moolenaar F, de Leede LGJ, et al. Rectal drug administration: clinical pharmacokinetic considerations. Clin Pharmacokinet 1982; 7: 285-311
57. Lemmer B, Bruguerolle B. Chronopharmacokinetics: are they clinically relevant? Clin Pharmacokinet 1994; 26: 419-27
58. Lemmer B, Scheidel B, Benne S. Chronopharmacokinetics and chronopharmacodynamics of cardiovascular active drugs. Propranolol, organic nitrates, nifedipine. Ann NY Acad Sci 1991; 618: 166-81
59. Lemmer B, Nold G, Behne S, et al. Chronopharmacokinetics and cardiovascular effects of nifedipine. Chronobiol Int 1991; 8: 485-94
60. Lemmer B. The cardiovascular system and daily variation in response to antihypertensive and antianginal drugs: recent advances. Pharmacol Ther 1991; 51: 269-74
61. Shargel L, Yu ABC. Applied biopharmaceutics and pharmacokinetics. 3rd ed. Norwalk (CN): Appleton and Lange, 1993
62. Castañeda-Hernández G, Caille G, du Souich P. Influence of drug formulation on drug concentration-effect relationships. Clin Pharmacokinet 1994; 26 (2): 135-43
63. Castañeda-Hernández G, Hoyo-Vadillo C, Herrera JE. Differences in nifedipine concentration-effect relationship between capsule and slow release tablet administration. Int J Clin Pharmacol Ther 1995; 33 (1): 56-60
64. Myers MG, Tanner J, Leenen FHH, et al. Comparative efficacy of two long-acting formulations of nifedipine in the treatment of hypertension [abstract]. Presented at the 9th Scientific Meeting of the American Society of Hypertension, 1994
65. Davis SS, Hardy JG, Taylor MJ, et al. The in-vivo evaluation of an osmotic device (Osmet) using gamma scintigraphy. J Pharm Pharmacol 1984; 36: 740-2
66. Mojaverian P, Chan K, Desai A, et al. Gastrointestinal transit of a solid indigestible capsule as measured by radiotelemetry and dual gamma scintigraphy. Pharm Res 1989; 6 (8): 719-24
67. Wilson CG, Hardy JG. Gastrointestinal transit of an osmotic tablet drug delivery system. J Pharm Pharmacol 1985; 37: 573-5
68. Davis SS, Washington N, Parr GD, et al. Relationship between the rate of appearance of oxprenolol in the systemic circulation and the location of an oxprenolol Oros 16/260 drug delivery system within the gastrointestinal tract as determined by scintigraphy. Br J Clin Pharmacol 1988; 26: 435-43
69. John VA, Shotton PA, Moppert J, et al. Gastrointestinal transit of Oros drug delivery systems in healthy volunteers: a short report. Br J Clin Pharmacol 1985; 19 Suppl. 2: 203S-206S
70. Hirtz J. The absorption window: fact or fiction? Pharm Int 1984; 175-8
71. Harey JG, Wilson CG, Wood E. Drug delivery to the proximal colon. J Pharm Pharmacol 1985; 37: 874-7
72. Metcalf AM, Phillips SF, Zinsmeister AR, et al. Simplified assessment of segmental colonic transit. Gastroenterology 1987; 92: 40-7
73. Prisant LM, Carr AA, Bottini PB, et al. Nifedipine GITS (gastrointestinal therapeutic system) bezoar. Arch Intern Med 1991; 151: 1868-9
74. Greenstein DB, Wilcox CM, Frontin K, et al. Nifedipine (Procaidia XL) as a cause of false-positive results on barium enema study. South Med J 1994; 87 (8): 808-10
75. Adalat XL® Product Monograph. Etobicoke, Ontario: Bayer Canada Inc., 1995
76. Ritschel WA. Diseases and disease states that influence gastrointestinal absorption of drugs. J Pharmaceut Sci 1993; 82 (9): 862-5
77. Bailey DG, Arnold JM, Spence JD. Grapefruit juice and drugs: How significant is the interaction? Clin Pharmacokinet 1994; 26 (2): 91-8
78. Bailey DG, Spence JD, Munoz C, et al. Interaction of citrus juices with felodipine and nifedipine. Lancet 1991; 337: 268-9
79. Rashid J, Mckinstry C, Renwick AG, et al. Quercetin, an in vitro inhibitor of CYP3A, does not contribute to the interaction between nifedipine and grapefruit juice. Br J Clin Pharmacol 1993; 36: 460-3
80. Tam YK. Individual variation in first-pass metabolism. Clin Pharmacokinet 1993; 25 (4): 300-28
81. Bailey DG, Arnold MO, Bend JR, et al. Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation. Br J Clin Pharmacol 1995; 40: 315-40
82. Graefe KH, Ziegler R, Wingender W, et al. Plasma concentration -response relationships for some cardiovascular effects of dihydropyridines in healthy subjects. Clin Pharmacol Ther 1988; 43 (1): 16-22
83. Opie LH. Calcium antagonists. Mechanisms, therapeutic indications and reservations: a review. Q J Med 1984; NS LIII (209): 1-16
84. Zsotée TT, Church JG. Calcium antagonists. Pharmacodynamic effects and mechanism of action. Drugs 1983; 25: 93-112
85. Borchard U. Calcium antagonists in comparison: view of the pharmacologist. J Cardiovasc Pharmacol 1994; 24 Suppl. 2: S85-91
86. Frishman WH, Garofalo JL, Rothschild A, et al. The nifedipine gastrointestinal therapeutic system in the treatment of hypertension. Am J Cardiol 1989; 64: 65F-69F
87. Frohlich HD, McLoughlin MJ, Losem CJ, et al. Hemodynamic comparison of two nifedipine formulations in patients with essential hypertension. Am J Cardiol 1991; 68: 1346-50
88. Hilleman DE, Mohiuddin SM, Lucas Jr BD, et al. Conversion from sustained-release to immediate-release calcium entry blockers: outcome in patients with mild-to-moderate hypertension. Clin Ther 1993; 15 (6): 1002-10
89. Vetrovee GW, Parker VE, Cole S, et al. Nifedipine gastrointestinal therapeutic system in stable angina pectoris. Results of a multicenter open-label crossover comparison with standard nifedipine. Am J Med 1987; 83 Suppl. 6B: 24-9
90. Hosie J, Bremner AD, Fell PJ, et al. Side effects of dihydropyridine therapy: comparison of amlodipine and nifedipine retard. J Cardiovasc Pharmacol 1993; 22 Suppl. A: S9-12
91. Galletti F, Barba G, Nardecchia A, et al. Controlled study with a new sustained-release formulation of nifedipine in essential hypertensive patients. J Clin Pharmacol 1994; 34: 919-23
92. Rogstad B. A comparison of lisinopril and nifedipine in the treatment of mild to moderate hypertension. A multicentre study. Eur J Clin Pharmacol 1994; 46: 487-9
93. Mörlin C, Baglivo H, Boeijinga JK, et al. Comparative trial of lisinopril and nifedipine in mild to severe essential by pertension. J Cardiovasc Pharmacol 1987; 9 Suppl. 3: S49-52
94. Feig PU, Gibson L, Mac Carthy EP, et al. The efficacy and safety of once-daily nifedipine coat-core in the treatment of mild-to-moderate hypertension. Adalat CC Cooperative Study Group [published erratum appears in Clin Ther 1994 Jan-Leb; 16 (1): 125]. Clin Ther 1993; 15 (6): 963-75
95. Glasser SP, Jain A, Allenby KS, et al. The efficacy and safety of once-daily nifedipine: the coat-core formulation compared with the gastrointestinal therapeutic system formulation in patients with mild-to-moderate diastolic hypertension. Nifedipine Study Group. Clin Ther 1995; 17 (1): 12-29
96. Fagan TC, Haggert BE, Liss C. Efficacy and tolerability of extended-release felodipine and extended-release nifedipine in patients with mild-to-moderate essential hypertension. Clin Ther 1994; 16: 634-46
97. Frishman WH, Garofalo JL, Rothschild A, et al. Multicenter comparison of the nifedipine gastrointestinal therapeutic system and long-acting propranolol in patients with mild to moderate systemic hypertension receiving diuretics. A preliminary experience. Am J Med 1987; 83 Suppl. 6B: 15-9
98. Gavras I, Mulinari R, Gavras H, et al. Antihypertensive effectiveness of the nifedipine gastrointestinal therapeutic system. Am J Med 1987; 83 Suppl. 6B: 20-3
99. Krakoff LR, Bravo EL, Tuck ML, et al. Nifedipine gastrointestinal therapeutic system in the treatment of hypertension. Results of a multicenter trial. The Modern Approach to the Treatment of Hypertension (MATH) Study Group. Am J Hypertens 1990; 3 (12 Pt 2): 318S-327S
100. Murphy C, McNamara C, Mohanty PK. The antihypertensive effects of nifedipine (GITS) in mild to moderate hypertension [abstract]. Am J Hypertens 1989; 2 (5 Pt 2): 28A
101. Lewis GP, Ames RP, Halperin AK, et al. Nifedipine gastrointestinal therapeutic system (NGITS) in patients with mild essential hypertension: therapeutic effects of a novel delivery system [abstract]. Am J Hypertens 1989; 2 (5 Pt 2): 18A
102. Houston MC, Olafsson L, Burger MC. Effects of nifedipine GITS and atenolol monotherapy on serum lipids, blood pressure, heart rate, and weight in mild to moderate hypertension. Angiology 1991; 42 (9): 681-90
103. Zanchetti A, Bianchi L, Amigoni S, et al. Antihypertensive effects of nifedipine gastrointestinal therapeutic system on clinic and ambulatory blood pressure in essential hypertensives. J Hypertens 1993; 11 Suppl. 5: S334-5
104. Zanchetti A. The 24-hour efficacy of a new once-daily formulation of nifedipine. Italian Nifedipine GITS Study Group. Drugs 1994; 48 Suppl. 1: 23-30
105. Tuck ML, Bravo EL, Krakoff LR, et al. Endocrine and renal effects of nifedipine gastrointestinal therapeutic system in patients with essential hypertension. Results of a multicenter trial. The Modern Approach to the Treatment of Hypertension Study Group. Am J Hypertens 1990; 3 (12 Pt 2): 333S-341S
106. Krakoff LR. Effectiveness of nifedipine gastrointestinal therapeutic system for treatment of hypertension: results of the MATH Trial. J Cardiovasc Pharmacol 1993; 21 Suppl. 2: S14-7
107. Zanchetti A. Short- and long-term perspectives of antihypertensive therapy. An introduction. Am J Hypertens 1993; 6 (3 Pt 2): 2S-5S
108. Mancia G, Frattola A, Omboni S, et al. Twenty-four-hour blood pressure and antihypertensive treatment. Blood Press 1992; Suppl. 1: 44-6
109. Meredith PA, Elliott HL. FDA guidelines on trough: peak ratios in the evaluation of antihypertensive agents. J Cardiovasc Pharmacol 1994; 23 Suppl. 5: S26-30
110. Donnelly R, Elliott HL, Meredith PA. Concentration-effect analysis of antihypertensive drug response. Focus on calcium antagonists. Clin Pharmacokinet 1994; 26 (6): 472-85
111. Meredith PA, Donnelly R, Elliott HL, et al. Prediction of the antihypertensive response to enalapril. J Hypertens 1990; 8: 1085-90
112. Bainbridge AD, Herlihy O, Meredith PA, et al. A comparative assessment of amlodipine and felodipine ER: pharmacokinetic and pharmacodynamic indices. Eur J Clin Pharmacol 1993; 45: 425-30
113. Glasser SP, Ripa SR, Allenby KS, et al. The efficacy and safety of once-daily nifedipine administered without food: the coat-core formulation compared with the gastrointestinal therapeutic system formulation in patients with mild-to-moderate hypertension. Clin Ther 1995; 17 (2): 296-312
114. Echizen H, Eichelbaum M. Clinical pharmacokinetics of verapamil, nifedipine and diltiazem. Clin Pharmacokinet 1986; 11: 425-49
115. Meredith PA, Elliott HL, Donnelly R, et al. Dose-response clarification in early drug development. J Hypertens 1991; 9 Suppl. 6: S356-7
116. Donnelly R, Elliott HL, Meredith PA, et al. Nifedipine: individual responses and concentration-effect relationships. Hypertension 1988; 12 (4): 443-9
117. Banerjee PS, Robinson JR. Novel drug delivery systems: an overview of their impact on clinical pharmacokinetic studies. Clin Pharmacokinet 1991; 20 (1): 1-14
118. Francheteau P, Steimer JL, Merdjan H, et al. A mathematical model for dynamics of cardiovascular drug action: application to intravenous dihydropyridines in healthy volunteers. J Pharmacokinet Biopharmaceut 1993; 21 (5): 489-514
119. Castañeda-Hernández G, Hoyo C, Herrera JE, et al. Comparacion farmacocinetica de dos formulaciones orales de nifedipina: capsula de 10 mg y tableta de liberacion prolongada de 20 mg [abstract]. Memorias del XV Congreso Nacional de Cardiololgia, Villahermosa, Mexico. 1987; 214
120. Breimer DD, Urquhart J. Nifedipine GITS [correspondence]. Lancet 1993; 341: 306
121. Nifedipine: a new life with GITS? [editorial]. Lancet 1992; 340: 1507-8
122. Nayler WG. Pharmacological aspects of calcium antagonism: short term and long term benefits. Drugs 1993; 46 Suppl. 2: 40-7
123. Sewester CS, Olin BR, Hebel SK, et al. Facts and comparisons. New York: J.B. Lippincott Co., 1991
124. Opie LH, White DA. Adverse interaction between nifedipine and beta-blockade. Br Med J 1980; 281 (6253): 1462
125. Monsen L, Moisey D, Gaffney M, et al. Consistent blood pressure reduction without loss of diurnal variability with once-daily nifedipine GITS treatment [abstract]. Am J Hypertens 1990; 3 (5 Pt 2): 114A
126. Geizhals M, Phillips RA, Ardeljan M, et al. Sustained calcium channel blockade in the treatment of severe hypertension. A two year experience. Am J Hypertens 1990; 3: 313S-317S
127. Martsevich SY, Metelitsa VI, Rumiantsev DO, et al. Development of tolerance to nifedipine in patients with stable angina pectoris. Br J Clin Pharmacol 1990; 29: 339-46
128. Salvetti A, Di Venanzio L. Clinical pharmacology of long-acting calcium antagonists: what relevance for therapeutic effects? J Cardiovasc Pharmacol 1994; 23 Suppl. 5: S31-4
129. Oosterhuis B, Jonkman JH. Advantages and disadvantages of reformulation of older drugs. Clin Pharmacokinet 1993; 25 (3): 165-71
130. Elliott HL, Meredith PA. Nifedipine GITS [correspondence]. Lancet 1993; 341: 306
131. Rudd P, Lenert L. Pharmacokinetics as an aid to optimising compliance with medications. Clin Pharmacokinet 1995; 28 (1): 1-6